Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 4, 2010, Pages 1846-1850

  Imel, Erik A ^a   DiMeglio, Linda A ^a   Hui, Siu L ^a   Carpenter, Thomas O ^b   Econs, Michael J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; CALCIUM CHANNEL STIMULATING AGENT; FIBROBLAST GROWTH FACTOR; PHOSPHORUS;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; HUMAN; MALE; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; STANDARD; TERTIARY HEALTH CARE; THERAPY EFFECT; TREATMENT DURATION; X LINKED HYPOPHOSPHATEMIC RICKETS; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; INFANT;

ADOLESCENT; ADULT; CALCITRIOL; CALCIUM CHANNEL AGONISTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HUMANS; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; INFANT; PHOSPHATES; PHOSPHORUS; PROSPECTIVE STUDIES;

EID: 77951626687     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1671     Document Type: Article

References (20)

1. Hyp-Consortium 1995 A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 11:130-136
2. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD 2003 Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419-37426
3. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429-435
4. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD 2006 Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305-1315
5. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663 (Pubitemid 36459471)
6. Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T 2008 Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients. Proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235-1239
7. Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK 1985 Healing of bone disease in X-linked hypophosphatemic rickets/ osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest 75:1858-1868
8. Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M 1991 Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 325:1843-1848
9. Rivkees SA, el-Hajj-Fuleihan G, Brown EM, Crawford JD 1992 Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab 75:1514-1518
10. Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M, Miyamoto K 2005 Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288:E1101-E1109
11. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N 2005 Circulating FGF-23 is regulated by 1α,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543-2549
12. Burnett SM, Gunawardene SC, Bringhurst FR, Jüppner H, Lee H, Finkelstein JS 2006 Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21: 1187-1196 (Pubitemid 44128331)
13. Tenenhouse HS, Econs MJ 2001 Mendelian hypophosphatemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular basis of inherited disease, 8th ed. New York: McGraw Hill; 5039-5067
14. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960
15. Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y 2005 A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res 58:329-333
16. Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ 2006 Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055-2061
17. Econs MJ, Samsa GP, Monger M, Drezner MK, Feussner JR 1994 X-linked hypophosphatemic rickets: a disease often unknown to affected patients. Bone Miner 24:17-24 (Pubitemid 24071555)
18. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA 2005 Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146:5358-5364
19. Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD 2008 Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 3:658-664
20. Imel EA, Hui SL, Econs MJ 2007 FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520-526